Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Amarin Corporation plc (ADR) - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AMRN
Nasdaq
2834
https://amarincorp.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Amarin Corporation plc (ADR)
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
- Mar 25th, 2024 12:00 pm
Amarin Full Year 2023 Earnings: Beats Expectations
- Mar 5th, 2024 1:09 pm
Earnings Update: Amarin Corporation plc (NASDAQ:AMRN) Just Reported And Analysts Are Trimming Their Forecasts
- Mar 2nd, 2024 1:00 pm
Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates
- Mar 1st, 2024 2:30 pm
Amarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Call Transcript
- Mar 1st, 2024 1:39 pm
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript
- Feb 29th, 2024 8:30 pm
Amarin Corp PLC (AMRN) Faces Revenue Decline Amidst Generic Competition
- Feb 29th, 2024 12:34 pm
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Feb 29th, 2024 12:00 pm
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
- Feb 15th, 2024 1:00 pm
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
- Feb 15th, 2024 10:45 am
Amarin Chairman & CEO Issue Letter to Shareholders
- Jan 22nd, 2024 12:30 pm
Are Medical Stocks Lagging Amarin (AMRN) This Year?
- Jan 12th, 2024 2:40 pm
Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results
- Jan 11th, 2024 2:34 pm
Why Amarin Stock Skyrocketed Today
- Jan 11th, 2024 12:02 am
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
- Jan 10th, 2024 12:00 pm
13 Most Promising Small-Cap Stocks According to Analysts
- Dec 27th, 2023 12:13 am
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Dec 11th, 2023 1:00 pm
Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?
- Dec 8th, 2023 4:30 pm
What Makes Amarin (AMRN) a New Buy Stock
- Dec 5th, 2023 5:00 pm
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
- Nov 12th, 2023 2:00 pm
Scroll